Last updated: August 16, 2022
Sponsor: Kantonsspital Aarau
Overall Status: Active - Recruiting
Phase
N/A
Condition
Cancer (Pediatric)
Retinoblastoma
Neuroblastoma
Treatment
N/AClinical Study ID
NCT04284189
2018-02304
Ages > 16 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 5-year survivor of childhood cancer
- Diagnosis according to ICCC3 I-XII; Langerhans cell histiocytosis (LCH),Hemophagocytic lymphohistiocytosis (HLH)
- Age at diagnosis <18 years
- Age at study ≥16 years
- At study start in follow-up care at one of the three pediatric oncology centers (groupbefore transition) or transitioned not before 2014 (group after transition).
- Written informed consent
Exclusion
Exclusion Criteria:
- Treatment only by means of surgery and without increased risk of late effects (e.g.teratoma)
- <5 years after therapy of a relapse or palliative situation
- Severe cognitive impairment, which makes it impossible to complete the questionnaireindependently
- Insufficient knowledge of the German language
- Informed consent form not signed
Study Design
Total Participants: 140
Study Start date:
February 12, 2019
Estimated Completion Date:
August 31, 2030
Study Description
Connect with a study center
Division of Oncology - Hematology, Department of Pediatrics, Kantonsspital Aarau
Aarau,
SwitzerlandActive - Recruiting
Division of Oncology/ Hematology, University Children's Hospital Basel
Basel,
SwitzerlandActive - Recruiting
Division of Oncology/ Hematology, Department of Pediatrics, Kantonsspital Lucerne
Lucerne,
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.